NPPA caps prices of 70 new drugs

This is part of the new drug pricing control order notified on March 14, which effectively brings 200 more drug formulations under regulation

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-86351161/stock-photo-many-pills-and-tablets-isolated-on-white-background.html" target="_blank">Image</a> via Shutterstock
Deepak Patel New Delhi
Last Updated : Apr 14 2016 | 12:26 AM IST

Don't want to miss the best from Business Standard?

On March 29, the NPPA had capped the prices of 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis and high blood pressure

The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 70 new drugs. This is part of the new drug pricing control order notified on March 14, which effectively brings 200 more drug formulations under regulation.

Anti-cancer drug Rituximab, which is sold by just four companies in India, saw its price capped at Rs 704 for one unit (milli litre). Dr Reddy's has 50 per cent market share for this drug. Pneumonia drug Piperacillin/tazobactam, which has annual sales of Rs 368 crore in India, has its price capped at Rs 408 a unit (milli litre). Alkem Labs, Cipla, Macleods, Ipca Labs and Emcure Pharma produce this drug.

Bortezomib, another anti-cancer drug where the market is dominated by Emcure Pharma and Dr Reddy's, saw its price capped as well. Anti-malaria drug Artesunate, which has annual sales of Rs 106 crore in India, has got its price capped at Rs 194 a unit (milli litre).

Zolpidem, which is used to cure insomnia and certain brain disorders, now has a ceiling price of Rs 8 per tablet. Abbott controls 70 per cent of this drug's market. Zolpidem has annual sales of Rs 42 crore in India.

On March 29, the NPPA had capped the prices of 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, hepatitis C and diabetes.

In December 2015, while issuing a new National List of Essential Medicines (NLEM), the government had added 106 and removed 70 medicines from the earlier one of 2011, expanding the list to 376 from 348 earlier.

Based on the new NLEM, the government on March 14 notified the Drugs (Price Control) Amendment Order, 2016. It has about 820 formulations. There were 628 formulations under the Drug Price Control Order of 2013, notified in the wake of the NLEM of 2011.

Whenever there is a new NLEM, the government has to issue a new price control order and NPPA needs to set their ceiling prices subsequently.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 14 2016 | 12:21 AM IST

Next Story